Search company, investor...
Swift Biosciences company logo

Swift Biosciences


Acquired | Acquired

Total Raised


About Swift Biosciences

Swift Biosciences develops and commercializes NGS Library Preparation Kits that enable technologies for genomics, translational, and clinical research. Its proprietary technologies expand the range of sample inputs to extend the applications of next-generation sequencing (NGS). Swift Library Kits are designed to maximize data output, provide the most comprehensive coverage available on the market, and reduce sequencing costs. The company's products are designed to facilitate library normalization and to analyze DNA and RNA samples for applications including Liquid Biopsy (circulating, cell-free DNA), Methylation Sequencing, Whole Genome, Exome and Transcriptome Sequencing as well as Chromatin studies, from low input quantities and from Formalin-Fixed, Paraffin-Embedded samples. The mission of Swift Biosciences is to provide research tools for long-term improvements in the health of individuals and their communities all around the world, specifically in the fight against cancer and understanding the complexities of inherited diseases. The tools developed in its efforts are directly applicable to research in agrigenomics, biotechnology, metagenomics, and the pharmaceutical industry. On March 11th, 2021, Swift Biosciences was acquired by Integrated DNA Technologies. The terms of the transaction were not disclosed.

Headquarters Location

674 S. Wagner Road Suite 100

Ann Arbor, Michigan, 48103,

United States


Missing: Swift Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Swift Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Swift Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Swift Biosciences is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Swift Biosciences Patents

Swift Biosciences has filed 23 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA, Biotechnology, DNA sequencing, Genetics


Application Date


Grant Date



Related Topics

Molecular biology, DNA, Biotechnology, DNA sequencing, Genetics



Latest Swift Biosciences News

CRISPR Technology Global Market Report 2023: Usage in Diagnostics Set to Catalyse Growth

Feb 16, 2023

News provided by Share this article Share this article DUBLIN, Feb. 15, 2023 /PRNewswire/ -- The "CRISPR Technology Global Market Report 2023" report has been added to's offering. The global crispr technology market will grow from $1.33 billion in 2022 to $1.65 billion in 2023 at a compound annual growth rate (CAGR) of 24.6%. The CRISPR technology market is expected to grow to $3.77 billion in 2027 at a CAGR of 22.9%. North America was the largest region in the CRISPR technology market in 2022. Western Europe was the second largest region in the CRISPR technology market. The regions covered in the CRISPR technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services. Stringent government regulations are expected to limit the growth of the CRISPR technology market during the period. There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing. The Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation. According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the market. Several advancements in CRISPR technology are trending in the market during the period. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more. In 2020, astudy in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR-Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes. In March 2021, Integrated DNA Technologies (IDT), a US-based genomics solutions provider, acquired Swift Biosciences. The acquisition aimed at leveraging Swift's academic and clinical research in next-generation sequencing. Swift Biosciences is a US-based company involved in creating genomics kits to prepare Next-Generation Sequencing (NGS) libraries. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Scope 3. CRISPR Technology Market Trends And Strategies 4. CRISPR Technology Market - Macro Economic Scenario 5. CRISPR Technology Market Size And Growth 6. CRISPR Technology Market Segmentation 7. CRISPR Technology Market Regional And Country Analysis 8. Asia-Pacific CRISPR Technology Market 9. China CRISPR Technology Market 10. India CRISPR Technology Market 11. Japan CRISPR Technology Market 12. Australia CRISPR Technology Market 13. Indonesia CRISPR Technology Market 14. South Korea CRISPR Technology Market 15. Western Europe CRISPR Technology Market 16. UK CRISPR Technology Market 17. Germany CRISPR Technology Market 18. France CRISPR Technology Market 19. Eastern Europe CRISPR Technology Market 20. Russia CRISPR Technology Market 21. North America CRISPR Technology Market 22. USA CRISPR Technology Market 23. South America CRISPR Technology Market 24. Brazil CRISPR Technology Market 25. Middle East CRISPR Technology Market 26. Africa CRISPR Technology Market 27. CRISPR Technology Market Competitive Landscape And Company Profiles 28. Key Mergers And Acquisitions In The CRISPR Technology Market 29. CRISPR Technology Market Future Outlook and Potential Analysis 30. Appendix

Swift Biosciences Frequently Asked Questions (FAQ)

  • Where is Swift Biosciences's headquarters?

    Swift Biosciences's headquarters is located at 674 S. Wagner Road, Ann Arbor.

  • What is Swift Biosciences's latest funding round?

    Swift Biosciences's latest funding round is Acquired.

  • How much did Swift Biosciences raise?

    Swift Biosciences raised a total of $35.13M.

  • Who are the investors of Swift Biosciences?

    Investors of Swift Biosciences include Integrated DNA Technologies, Paycheck Protection Program, Mercury Fund, Fletcher Spaght Ventures, MissionPoint Partners and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.